Supplements

In this supplement to Cardiology News, John R. Nelson, MD, FACC, FNLA, FASNC, and Matthew J. Budoff, MD, discuss results from RESPECT-EPA and the existing evidence that purified eicosapentaenoic acid significantly reduces residual CV risk in patients with CVD.
 

Read More

In this supplement to Cardiology News, John R. Nelson, MD, FACC, FNLA, FASNC, and Matthew J. Budoff, MD, discuss results from RESPECT-EPA and the existing evidence that purified eicosapentaenoic acid significantly reduces residual CV risk in patients with CVD.
 

Read More

In this supplement to Cardiology News, John R. Nelson, MD, FACC, FNLA, FASNC, and Matthew J. Budoff, MD, discuss results from RESPECT-EPA and the existing evidence that purified eicosapentaenoic acid significantly reduces residual CV risk in patients with CVD.
 

Read More

In this supplement to Cardiology News, Payal Kohli, MD, FACC, and Nihar Desai, MD, MPH, discuss the PROMINENT trial and the debate on avoiding the use of fibrates for cardiovascular risk reduction. 

Read More


 

In this supplement to Cardiology News, Payal Kohli, MD, FACC, and Nihar Desai, MD, MPH, discuss the PROMINENT trial and the debate on avoiding the use of fibrates for cardiovascular risk reduction. 

Read More


 

In this supplement to Cardiology News, Payal Kohli, MD, FACC, and Nihar Desai, MD, MPH, discuss the PROMINENT trial and the debate on avoiding the use of fibrates for cardiovascular risk reduction. 

Read More


 

Lewis Blevins, MD; Richard Auchus, MD, PhD; David Brown, MD, PhD; Amir Hamrahian, MD; and Smita Kargutkar, MD share their insights and real-world perspectives on hypercortisolism diagnosis and management, including:

• The understanding of hypercortisolism has evolved significantly over the past decades to extend beyond classic physical manifestations (e.g., central obesity, facial plethora, buffalo hump, purple striae)

• Early identification of patients with mild autonomous cortisol secretion is important as hypercortisolism can lead to age-inappropriate and treatment-resistant metabolic syndrome

• Patient identification and management approaches for hypercortisolism can differ between academic and community settings due to differences in available resources and multidisciplinary management teams

• Educating primary care providers and community endocrinologists about the consequences of hypercortisolism can be beneficial in bridging the gap between academic and community settings

Lewis Blevins, MD Meeting Moderator University of California San Francisco   San Francisco, CA	Richard Auchus, MD, PhD University of Michigan Ann Arbor, MI	David Brown, MD, PhD Private Practice Rockville, MD
Amir Hamrahian, MD Johns Hopkins University Baltimore, MD	Smita Kargutkar, MD ACE Endocrinology Associates Red Bank, NJ

Click HERE to read the supplement.

©2022 Corcept Therapeutics Incorporated. All Rights Reserved. DSE-00997 DEC 2022

Lewis Blevins, MD; Richard Auchus, MD, PhD; David Brown, MD, PhD; Amir Hamrahian, MD; and Smita Kargutkar, MD share their insights and real-world perspectives on hypercortisolism diagnosis and management, including:

• The understanding of hypercortisolism has evolved significantly over the past decades to extend beyond classic physical manifestations (e.g., central obesity, facial plethora, buffalo hump, purple striae)

• Early identification of patients with mild autonomous cortisol secretion is important as hypercortisolism can lead to age-inappropriate and treatment-resistant metabolic syndrome

• Patient identification and management approaches for hypercortisolism can differ between academic and community settings due to differences in available resources and multidisciplinary management teams

• Educating primary care providers and community endocrinologists about the consequences of hypercortisolism can be beneficial in bridging the gap between academic and community settings

Lewis Blevins, MD Meeting Moderator University of California San Francisco   San Francisco, CA	Richard Auchus, MD, PhD University of Michigan Ann Arbor, MI	David Brown, MD, PhD Private Practice Rockville, MD
Amir Hamrahian, MD Johns Hopkins University Baltimore, MD	Smita Kargutkar, MD ACE Endocrinology Associates Red Bank, NJ

Click HERE to read the supplement.

©2022 Corcept Therapeutics Incorporated. All Rights Reserved. DSE-00997 DEC 2022

Lewis Blevins, MD; Richard Auchus, MD, PhD; David Brown, MD, PhD; Amir Hamrahian, MD; and Smita Kargutkar, MD share their insights and real-world perspectives on hypercortisolism diagnosis and management, including:

• The understanding of hypercortisolism has evolved significantly over the past decades to extend beyond classic physical manifestations (e.g., central obesity, facial plethora, buffalo hump, purple striae)

• Early identification of patients with mild autonomous cortisol secretion is important as hypercortisolism can lead to age-inappropriate and treatment-resistant metabolic syndrome

• Patient identification and management approaches for hypercortisolism can differ between academic and community settings due to differences in available resources and multidisciplinary management teams

• Educating primary care providers and community endocrinologists about the consequences of hypercortisolism can be beneficial in bridging the gap between academic and community settings

Lewis Blevins, MD Meeting Moderator University of California San Francisco   San Francisco, CA	Richard Auchus, MD, PhD University of Michigan Ann Arbor, MI	David Brown, MD, PhD Private Practice Rockville, MD
Amir Hamrahian, MD Johns Hopkins University Baltimore, MD	Smita Kargutkar, MD ACE Endocrinology Associates Red Bank, NJ

Click HERE to read the supplement.

©2022 Corcept Therapeutics Incorporated. All Rights Reserved. DSE-00997 DEC 2022

Read More

‌

‌

‌

Read More

‌

‌

‌

Read More

‌

‌

‌

INTRODUCTION

Editor’s note
By Glenn S. Williams
Our 7th annual issue highlights several notable FDA approvals in 2021 and early 2022, emerging genetic therapies for monogenetic disorders, and recent advances in rare disease diagnosis and testing.

A note from NORD
By Peter L. Saltonstall
As we approach NORD’s 40th anniversary, it is astonishing to realize how far we all have come since the early 1980s, when rare disease patients and their medical providers were essentially on their own to navigate the challenging waters of rare disease diagnosis and treatment.

CLINICAL REVIEWS

Health care providers should have higher suspicion for rare diseases
By Jeff Craven
Learning to recognize when a cluster of symptoms doesn’t fit a pattern is important, as patients and their providers tend to gravitate toward diagnoses they are used to seeing, rather than suspecting a disease outside a usual pattern.

The paradox of Pompe disease
By Jennie Smith
For nearly 2 decades, patients with even the most severe genetic mutations have been surviving on therapy. But clinicians must now contend with previously unknown manifestations of this rare muscular disease.

Rett syndrome: Looking to the future and the promise of gene therapy
By Courtney S. Ambrose and Barbara J. Bailus, PhD
Like many monogenic disorders, Rett syndrome is entering an exciting stage – at which the words “treatment” and “cure” can be spoken with intent and conviction, not just hopeful optimism.

Rare disease patient advocacy groups empowered by data
By Theodore Bosworth
On the IAMRARE platform, patient advocacy organizations are trained to conduct observational research and host natural history.

Myasthenia gravis: Finding strength in treatment options
By Peter van der Eb; Scarlet Toruno, MS; and Jason Laird, DMSc, MHS, MBA, PA-C
Although the treatment of myasthenia gravis might have once been considered stagnant, newer expert consensus and novel research are generating optimism for innovative therapies.

Spinal muscular atrophy: Patient care in the age of genetically targeted therapy
By Kelli Whitlock Burton
Newly available treatments have changed the natural history of SMA. Newborn screening, updated treatment guidelines, and treatment algorithms have likewise changed what can be clinically done for patients with SMA, but still questions remain.

The broad and challenging – but promising – landscape of peripheral neuropathy
By Yun Seo Lee; Jonathan Kosacki; Kanika Bhandari, PharmD; Amanda Tran, PharmD
This review of peripheral neuropathy summarizes the more common causative entities, diagnostic tools that can potentially be employed to identify the disorder, and treatments that are in use or being tested to prevent, slow, or reverse its effects.

NORD Rare Disease Centers of Excellence: A new network seeks to break down barriers in rare disease care
By Jennie Smith
“The goal was to find places that could help with unanswered questions, whether diagnostic questions or treatment questions. To identify places where a patient could reasonably expect to go and have a deeper dive – maybe an interdisciplinary deep dive.”

Staying alert for patients with narcolepsy
By Erik Greb
The chronic neurologic disorder entails not only excessive sleepiness but also social and professional challenges.

ONLINE-ONLY CONTENT

Novel gene-based therapies for neuromuscular diseases
By Nahomi Yewhalashet, MBS, and Larry J. Davis, PharmD
Novel gene-based therapies show significant potential for transforming the treatment of neuromuscular diseases such as amyotrophic lateral sclerosis, spinal muscular atrophy, and Duchenne muscular dystrophy.

The urgent need to diagnose Sanfilippo syndrome at an early age
By Theodore Bosworth
The quest for effective treatments is dependent on enrolling more children at a very young age, before loss of milestones.

INTRODUCTION

Editor’s note
By Glenn S. Williams
Our 7th annual issue highlights several notable FDA approvals in 2021 and early 2022, emerging genetic therapies for monogenetic disorders, and recent advances in rare disease diagnosis and testing.

A note from NORD
By Peter L. Saltonstall
As we approach NORD’s 40th anniversary, it is astonishing to realize how far we all have come since the early 1980s, when rare disease patients and their medical providers were essentially on their own to navigate the challenging waters of rare disease diagnosis and treatment.

CLINICAL REVIEWS

Health care providers should have higher suspicion for rare diseases
By Jeff Craven
Learning to recognize when a cluster of symptoms doesn’t fit a pattern is important, as patients and their providers tend to gravitate toward diagnoses they are used to seeing, rather than suspecting a disease outside a usual pattern.

The paradox of Pompe disease
By Jennie Smith
For nearly 2 decades, patients with even the most severe genetic mutations have been surviving on therapy. But clinicians must now contend with previously unknown manifestations of this rare muscular disease.

Rett syndrome: Looking to the future and the promise of gene therapy
By Courtney S. Ambrose and Barbara J. Bailus, PhD
Like many monogenic disorders, Rett syndrome is entering an exciting stage – at which the words “treatment” and “cure” can be spoken with intent and conviction, not just hopeful optimism.

Rare disease patient advocacy groups empowered by data
By Theodore Bosworth
On the IAMRARE platform, patient advocacy organizations are trained to conduct observational research and host natural history.

Myasthenia gravis: Finding strength in treatment options
By Peter van der Eb; Scarlet Toruno, MS; and Jason Laird, DMSc, MHS, MBA, PA-C
Although the treatment of myasthenia gravis might have once been considered stagnant, newer expert consensus and novel research are generating optimism for innovative therapies.

Spinal muscular atrophy: Patient care in the age of genetically targeted therapy
By Kelli Whitlock Burton
Newly available treatments have changed the natural history of SMA. Newborn screening, updated treatment guidelines, and treatment algorithms have likewise changed what can be clinically done for patients with SMA, but still questions remain.

The broad and challenging – but promising – landscape of peripheral neuropathy
By Yun Seo Lee; Jonathan Kosacki; Kanika Bhandari, PharmD; Amanda Tran, PharmD
This review of peripheral neuropathy summarizes the more common causative entities, diagnostic tools that can potentially be employed to identify the disorder, and treatments that are in use or being tested to prevent, slow, or reverse its effects.

NORD Rare Disease Centers of Excellence: A new network seeks to break down barriers in rare disease care
By Jennie Smith
“The goal was to find places that could help with unanswered questions, whether diagnostic questions or treatment questions. To identify places where a patient could reasonably expect to go and have a deeper dive – maybe an interdisciplinary deep dive.”

Staying alert for patients with narcolepsy
By Erik Greb
The chronic neurologic disorder entails not only excessive sleepiness but also social and professional challenges.

ONLINE-ONLY CONTENT

Novel gene-based therapies for neuromuscular diseases
By Nahomi Yewhalashet, MBS, and Larry J. Davis, PharmD
Novel gene-based therapies show significant potential for transforming the treatment of neuromuscular diseases such as amyotrophic lateral sclerosis, spinal muscular atrophy, and Duchenne muscular dystrophy.

The urgent need to diagnose Sanfilippo syndrome at an early age
By Theodore Bosworth
The quest for effective treatments is dependent on enrolling more children at a very young age, before loss of milestones.

INTRODUCTION

Editor’s note
By Glenn S. Williams
Our 7th annual issue highlights several notable FDA approvals in 2021 and early 2022, emerging genetic therapies for monogenetic disorders, and recent advances in rare disease diagnosis and testing.

A note from NORD
By Peter L. Saltonstall
As we approach NORD’s 40th anniversary, it is astonishing to realize how far we all have come since the early 1980s, when rare disease patients and their medical providers were essentially on their own to navigate the challenging waters of rare disease diagnosis and treatment.

CLINICAL REVIEWS

Health care providers should have higher suspicion for rare diseases
By Jeff Craven
Learning to recognize when a cluster of symptoms doesn’t fit a pattern is important, as patients and their providers tend to gravitate toward diagnoses they are used to seeing, rather than suspecting a disease outside a usual pattern.

The paradox of Pompe disease
By Jennie Smith
For nearly 2 decades, patients with even the most severe genetic mutations have been surviving on therapy. But clinicians must now contend with previously unknown manifestations of this rare muscular disease.

Rett syndrome: Looking to the future and the promise of gene therapy
By Courtney S. Ambrose and Barbara J. Bailus, PhD
Like many monogenic disorders, Rett syndrome is entering an exciting stage – at which the words “treatment” and “cure” can be spoken with intent and conviction, not just hopeful optimism.

Rare disease patient advocacy groups empowered by data
By Theodore Bosworth
On the IAMRARE platform, patient advocacy organizations are trained to conduct observational research and host natural history.

Myasthenia gravis: Finding strength in treatment options
By Peter van der Eb; Scarlet Toruno, MS; and Jason Laird, DMSc, MHS, MBA, PA-C
Although the treatment of myasthenia gravis might have once been considered stagnant, newer expert consensus and novel research are generating optimism for innovative therapies.

Spinal muscular atrophy: Patient care in the age of genetically targeted therapy
By Kelli Whitlock Burton
Newly available treatments have changed the natural history of SMA. Newborn screening, updated treatment guidelines, and treatment algorithms have likewise changed what can be clinically done for patients with SMA, but still questions remain.

The broad and challenging – but promising – landscape of peripheral neuropathy
By Yun Seo Lee; Jonathan Kosacki; Kanika Bhandari, PharmD; Amanda Tran, PharmD
This review of peripheral neuropathy summarizes the more common causative entities, diagnostic tools that can potentially be employed to identify the disorder, and treatments that are in use or being tested to prevent, slow, or reverse its effects.

NORD Rare Disease Centers of Excellence: A new network seeks to break down barriers in rare disease care
By Jennie Smith
“The goal was to find places that could help with unanswered questions, whether diagnostic questions or treatment questions. To identify places where a patient could reasonably expect to go and have a deeper dive – maybe an interdisciplinary deep dive.”

Staying alert for patients with narcolepsy
By Erik Greb
The chronic neurologic disorder entails not only excessive sleepiness but also social and professional challenges.

ONLINE-ONLY CONTENT

Novel gene-based therapies for neuromuscular diseases
By Nahomi Yewhalashet, MBS, and Larry J. Davis, PharmD
Novel gene-based therapies show significant potential for transforming the treatment of neuromuscular diseases such as amyotrophic lateral sclerosis, spinal muscular atrophy, and Duchenne muscular dystrophy.

The urgent need to diagnose Sanfilippo syndrome at an early age
By Theodore Bosworth
The quest for effective treatments is dependent on enrolling more children at a very young age, before loss of milestones.

Inside this issue:

• Comorbidities, Racial Disparities, and Geographic Differences in Asthma
  Navitha Ramesh, MD, FCCP
• Post-COVID-19 Effects
  Viren Kaul, MD, FCCP, FACP
• New Pathogens, COVID-19, and Antibiotic Resistance in the Field of Pneumonia
  Marcos I. Restrepo, MD, MSc, PhD, FCCP
• COPD Characteristics and Health Disparities
  Muhammad Adrish, MD, MBA, FCCP
• Reducing Tuberculosis Globally and the Impact of COVID-19
  Patricio Escalante, MD, MSc, FCCP and Paige K. Marty, MD
• New Treatment Pathways for Cystic Fibrosis
  David Finklea, MD
• Risk Assessment in Pulmonary Arterial Hypertension
  Sandeep Sahay, MD, MSc, FCCP, ATSF
• Rising Incidence of Bronchiectasis and Associated Burdens
  Anne E. O'Donnell, MD, FCCP
• ILD: Diagnostic Considerations and Socioeconomic Barriers
  Daniel Dilling, MD, FCCP, FACP, FAST
• Advances in Lung Cancer Diagnostics and Treatment
  Eric S. Edell, MD, FCCP

Inside this issue:

• Comorbidities, Racial Disparities, and Geographic Differences in Asthma
  Navitha Ramesh, MD, FCCP
• Post-COVID-19 Effects
  Viren Kaul, MD, FCCP, FACP
• New Pathogens, COVID-19, and Antibiotic Resistance in the Field of Pneumonia
  Marcos I. Restrepo, MD, MSc, PhD, FCCP
• COPD Characteristics and Health Disparities
  Muhammad Adrish, MD, MBA, FCCP
• Reducing Tuberculosis Globally and the Impact of COVID-19
  Patricio Escalante, MD, MSc, FCCP and Paige K. Marty, MD
• New Treatment Pathways for Cystic Fibrosis
  David Finklea, MD
• Risk Assessment in Pulmonary Arterial Hypertension
  Sandeep Sahay, MD, MSc, FCCP, ATSF
• Rising Incidence of Bronchiectasis and Associated Burdens
  Anne E. O'Donnell, MD, FCCP
• ILD: Diagnostic Considerations and Socioeconomic Barriers
  Daniel Dilling, MD, FCCP, FACP, FAST
• Advances in Lung Cancer Diagnostics and Treatment
  Eric S. Edell, MD, FCCP

Inside this issue:

• Comorbidities, Racial Disparities, and Geographic Differences in Asthma
  Navitha Ramesh, MD, FCCP
• Post-COVID-19 Effects
  Viren Kaul, MD, FCCP, FACP
• New Pathogens, COVID-19, and Antibiotic Resistance in the Field of Pneumonia
  Marcos I. Restrepo, MD, MSc, PhD, FCCP
• COPD Characteristics and Health Disparities
  Muhammad Adrish, MD, MBA, FCCP
• Reducing Tuberculosis Globally and the Impact of COVID-19
  Patricio Escalante, MD, MSc, FCCP and Paige K. Marty, MD
• New Treatment Pathways for Cystic Fibrosis
  David Finklea, MD
• Risk Assessment in Pulmonary Arterial Hypertension
  Sandeep Sahay, MD, MSc, FCCP, ATSF
• Rising Incidence of Bronchiectasis and Associated Burdens
  Anne E. O'Donnell, MD, FCCP
• ILD: Diagnostic Considerations and Socioeconomic Barriers
  Daniel Dilling, MD, FCCP, FACP, FAST
• Advances in Lung Cancer Diagnostics and Treatment
  Eric S. Edell, MD, FCCP

Inside this issue:

• The Impact of COVID-19 on Colorectal Cancer Screening Programs
  Rachel B. Issaka, MD, MAS
• Early Onset Colorectal Cancer: Trends in Incidence and Screening
  Aasma Shaukat, MD, MPH, AGAF
• Diversity in the Gastroenterology Workforce and its Implications for Patients
  Sandra M. Quezada, MD, MS, AGAF
• Trends in Surveillance and Management of Dysplasia in IBD
  Joseph D. Feuerstein, MD, AGAF
• Environmental Factors in IBD: Diet and Stress
  Ashwin Ananthakrishnan, MBBS, MPH
• Evolving Therapeutic Goals in Crohn’s Disease Management
  Ryan Ungaro, MD, MS
• Switching to Disposable Duodenoscopes: Risks and Rewards
  Rajesh N. Keswani, MD, MS
• Increasing Surveillance Programs and Expanding Treatment Options in HCC
  Amit Singal, MD, MS
• Achalasia Remains a Challenging Disorder for the Community Gastroenterologist
  Benson T. Massey, MD

Inside this issue:

• The Impact of COVID-19 on Colorectal Cancer Screening Programs
  Rachel B. Issaka, MD, MAS
• Early Onset Colorectal Cancer: Trends in Incidence and Screening
  Aasma Shaukat, MD, MPH, AGAF
• Diversity in the Gastroenterology Workforce and its Implications for Patients
  Sandra M. Quezada, MD, MS, AGAF
• Trends in Surveillance and Management of Dysplasia in IBD
  Joseph D. Feuerstein, MD, AGAF
• Environmental Factors in IBD: Diet and Stress
  Ashwin Ananthakrishnan, MBBS, MPH
• Evolving Therapeutic Goals in Crohn’s Disease Management
  Ryan Ungaro, MD, MS
• Switching to Disposable Duodenoscopes: Risks and Rewards
  Rajesh N. Keswani, MD, MS
• Increasing Surveillance Programs and Expanding Treatment Options in HCC
  Amit Singal, MD, MS
• Achalasia Remains a Challenging Disorder for the Community Gastroenterologist
  Benson T. Massey, MD

Inside this issue:

• The Impact of COVID-19 on Colorectal Cancer Screening Programs
  Rachel B. Issaka, MD, MAS
• Early Onset Colorectal Cancer: Trends in Incidence and Screening
  Aasma Shaukat, MD, MPH, AGAF
• Diversity in the Gastroenterology Workforce and its Implications for Patients
  Sandra M. Quezada, MD, MS, AGAF
• Trends in Surveillance and Management of Dysplasia in IBD
  Joseph D. Feuerstein, MD, AGAF
• Environmental Factors in IBD: Diet and Stress
  Ashwin Ananthakrishnan, MBBS, MPH
• Evolving Therapeutic Goals in Crohn’s Disease Management
  Ryan Ungaro, MD, MS
• Switching to Disposable Duodenoscopes: Risks and Rewards
  Rajesh N. Keswani, MD, MS
• Increasing Surveillance Programs and Expanding Treatment Options in HCC
  Amit Singal, MD, MS
• Achalasia Remains a Challenging Disorder for the Community Gastroenterologist
  Benson T. Massey, MD

Read More

Read More

Read More

Introduction

ICYMI articles featuring 9 important developments of the past year – and COVID is still here

By Christopher J. Harrison, MD

Table of contents

Antibiotics use and vaccine antibody levels
Commentary

Emerging tick-borne pathogen has spread to state of Georgia
Commentary

WHO, UNICEF warn about increased risk of measles outbreaks
Commentary

Babies die as congenital syphilis continues a decade-long surge across the U.S.
Commentary

Meningococcal vaccine shows moderate protective effect against gonorrhea
Commentary

Adolescents are undertested for STIs
Commentary

TB treatment can be shortened for most children: Study
Commentary

Nirsevimab protects healthy infants from RSV
Commentary

Norovirus vaccine candidates employ different approaches
Commentary

Introduction

ICYMI articles featuring 9 important developments of the past year – and COVID is still here

By Christopher J. Harrison, MD

Table of contents

Antibiotics use and vaccine antibody levels
Commentary

Emerging tick-borne pathogen has spread to state of Georgia
Commentary

WHO, UNICEF warn about increased risk of measles outbreaks
Commentary

Babies die as congenital syphilis continues a decade-long surge across the U.S.
Commentary

Meningococcal vaccine shows moderate protective effect against gonorrhea
Commentary

Adolescents are undertested for STIs
Commentary

TB treatment can be shortened for most children: Study
Commentary

Nirsevimab protects healthy infants from RSV
Commentary

Norovirus vaccine candidates employ different approaches
Commentary

Introduction

ICYMI articles featuring 9 important developments of the past year – and COVID is still here

By Christopher J. Harrison, MD

Table of contents

Antibiotics use and vaccine antibody levels
Commentary

Emerging tick-borne pathogen has spread to state of Georgia
Commentary

WHO, UNICEF warn about increased risk of measles outbreaks
Commentary

Babies die as congenital syphilis continues a decade-long surge across the U.S.
Commentary

Meningococcal vaccine shows moderate protective effect against gonorrhea
Commentary

Adolescents are undertested for STIs
Commentary

TB treatment can be shortened for most children: Study
Commentary

Nirsevimab protects healthy infants from RSV
Commentary

Norovirus vaccine candidates employ different approaches
Commentary

Federal Health Care Data Trends (click to view the digital edition) is a special supplement to Federal Practitioner highlighting the latest research and study outcomes related to the health of veteran and active-duty populations. 

In this issue:

• Vaccinations
• Mental Health and Related Disorders
• LGBTQ+ Veterans
• Military Sexual Trauma
• Sleep Disorders
• Respiratory Illnesses
• HIV Care in the VA
• Rheumatologic Diseases
• The Cancer-Obesity Connection
• Skin Health for Active-Duty Personnel
• Contraception
• Chronic Kidney Disease
• Cardiovascular Diseases
• Neurologic Disorders
• Hearing, Vision, and Balance

Federal Practitioner would like to thank the following experts for their review of content and helpful guidance in developing this issue: 

Kelvin N.V. Bush, MD, FACC, CCDS; Sonya Borrero, MD, MS; Kenneth L. Cameron, PhD, MPH, ATC, FNATA; Jason DeViva, PhD; Ellen Lockard Edens, MD; Leonard E. Egede, MD, MS; Amy Justice, MD, PhD; Stephanie Knudson, MD; Willis H. Lyford, MD; Sarah O. Meadows, PhD; Tamara Schult, PhD, MPH; Eric L. Singman, MD, PhD; Art Wallace, MD, PhD; Elizabeth Waterhouse, MD, FAAN

Federal Health Care Data Trends (click to view the digital edition) is a special supplement to Federal Practitioner highlighting the latest research and study outcomes related to the health of veteran and active-duty populations. 

In this issue:

• Vaccinations
• Mental Health and Related Disorders
• LGBTQ+ Veterans
• Military Sexual Trauma
• Sleep Disorders
• Respiratory Illnesses
• HIV Care in the VA
• Rheumatologic Diseases
• The Cancer-Obesity Connection
• Skin Health for Active-Duty Personnel
• Contraception
• Chronic Kidney Disease
• Cardiovascular Diseases
• Neurologic Disorders
• Hearing, Vision, and Balance

Federal Practitioner would like to thank the following experts for their review of content and helpful guidance in developing this issue: 

Kelvin N.V. Bush, MD, FACC, CCDS; Sonya Borrero, MD, MS; Kenneth L. Cameron, PhD, MPH, ATC, FNATA; Jason DeViva, PhD; Ellen Lockard Edens, MD; Leonard E. Egede, MD, MS; Amy Justice, MD, PhD; Stephanie Knudson, MD; Willis H. Lyford, MD; Sarah O. Meadows, PhD; Tamara Schult, PhD, MPH; Eric L. Singman, MD, PhD; Art Wallace, MD, PhD; Elizabeth Waterhouse, MD, FAAN

Federal Health Care Data Trends (click to view the digital edition) is a special supplement to Federal Practitioner highlighting the latest research and study outcomes related to the health of veteran and active-duty populations. 

In this issue:

• Vaccinations
• Mental Health and Related Disorders
• LGBTQ+ Veterans
• Military Sexual Trauma
• Sleep Disorders
• Respiratory Illnesses
• HIV Care in the VA
• Rheumatologic Diseases
• The Cancer-Obesity Connection
• Skin Health for Active-Duty Personnel
• Contraception
• Chronic Kidney Disease
• Cardiovascular Diseases
• Neurologic Disorders
• Hearing, Vision, and Balance

Federal Practitioner would like to thank the following experts for their review of content and helpful guidance in developing this issue: 

Kelvin N.V. Bush, MD, FACC, CCDS; Sonya Borrero, MD, MS; Kenneth L. Cameron, PhD, MPH, ATC, FNATA; Jason DeViva, PhD; Ellen Lockard Edens, MD; Leonard E. Egede, MD, MS; Amy Justice, MD, PhD; Stephanie Knudson, MD; Willis H. Lyford, MD; Sarah O. Meadows, PhD; Tamara Schult, PhD, MPH; Eric L. Singman, MD, PhD; Art Wallace, MD, PhD; Elizabeth Waterhouse, MD, FAAN